Antiviral activities of Janus-type nucleosides and their related oxime-intermediates

Liu, Jiang; Zhao, Hang; Zhou, Xinglong; He, Yang; Chen, Qianming

doi:10.1016/j.bmc.2018.12.014

Cited by 6 publications

(6 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the oximes, exquisite anti-HSV-1 activity was displayed by two compounds (Figure 13), both had low IC50 values of 0.05 and 0.04 µg/mL. Moreover the compounds shown in Figure 13 also presented antiviral activity against distinct viruses as Herpes simplex virus-II (HSV-2), influenza viruses (H3N2), coxsackievirus B3 (CVB3), Hepatitis B virus (HBV), Hepatitis B virus (HCV) and Human papillomavirus (HPV) [29]. The antiviral activity of E,Z isomers of Janus-type nucleoside against Herpes simplex virus-I (HSV-1) were tested by Liu et al Most oximes demonstrated improved anti-HSV-1 activity compared to the Janus-type nucleosides.…”

Section: The Antimicrobial Activitymentioning

confidence: 99%

Unsubstituted Oximes as Potential Therapeutic Agents

2020

View full text Add to dashboard Cite

Oximes, which are highly bioactive molecules, have versatile uses in the medical sector and have been indicated to possess biological activity. Certain oximes exist in nature in plants and animals, but they are also obtained by chemical synthesis. Oximes are known for their anti-inflammatory, antimicrobial, antioxidant and anticancer activities. Moreover, they are therapeutic agents against organophosphate (OP) poisoning. Two oximes are already commonly used in therapy. Due to these abilities, new oxime compounds have been synthesized, and their biological activity has been verified. Often, modification of carbonyl compounds into oximes leads to increased activity. Nevertheless, in some cases, oxime activity is connected to the activity of the substrate. Recent works have revealed that new oxime compounds can demonstrate such functions and thus are considered to be potential drugs for pathogenic diseases, as adjuvant therapy in various types of cancer and inflammation and as potential next-generation drugs against OP poisoning.

show abstract

Section: The Antimicrobial Activitymentioning

confidence: 99%

Unsubstituted Oximes as Potential Therapeutic Agents

2020

View full text Add to dashboard Cite

show abstract

“…Of the papers reviewed, three (2.19%) papers displayed that nectin had efficacy as a second-line treatments in HSV [ 17 , 28 , 73 ], three (2.19%) papers showed efficacy using amenamevir [ 21 , 43 , 95 ], three (2.19%) using methanol extract were effective in various cell line [ 24 , 32 , 39 ], two (1.46%) using monoclonal antibodies [ 27 , 46 ], two (1.46%) with arbidol [ 75 , 81 ], two (1.46%) with siRNA swarms [ 22 , 98 ], two (1.46%) using Cucumis melo sulfated pectin were effective in Vero cells [ 10 , 123 ], two (1.46%) using components from Olea europeae were effective in Vero cells [ 125 , 130 ]. In addition to this, two (1.46%) with griffithsin (GRFT) were effective in various cell lines [ 45 , 80 ], two (1.46%) with Morus alba L. (compounds from mulberry root bark extract) were effective in Vero cells [ 85 , 103 ], two (1.46%) using nucleosides were effective in Vero cells [ 41 , 76 ], two (1.46%) with botryosphaeran were effective in Vero cells [ 74 , 128 ], two (1.46%) monoterpenes were effective in Vero cells [ 34 , 92 ], two (1.46%) with almond skin extracts were effective in Vero cells [ 26 , 68 ], two (1.46%) using bortezomib were effective in HCL and Vero cells [ 83 , 99 ], two (1.46%) using various flavonoid compounds [ 25 , 97 ], and two (1.46%) papers using essential oils were effective in Vero cells [ 31 , 34 ], but one (0.73%) showed that essential oils were not effective [ 131 ].…”

Section: Reviewmentioning

confidence: 99%

A Systematic Review of Second-Line Treatments in Antiviral Resistant Strains of HSV-1, HSV-2, and VZV

Lince¹,

DeMario²,

Yang³

et al. 2023

Cureus

View full text Add to dashboard Cite

Drug-resistant variants of herpes simplex viruses (HSV) have been reported that are not effectively treated with first-line antiviral agents. The objective of this study was to evaluate available literature on the possible efficacy of second-line treatments in HSV and the use of second-line treatments in HSV strains that are resistant to first-line treatments. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a final search was conducted in six databases on November 5, 2021 for all relevant literature using terms related to antiviral resistance, herpes, and HSV. Eligible manuscripts were required to report the presence of an existing or proposed second-line treatment for HSV-1, HSV-2, or varicella zoster virus (VZV); have full-text English-language access; and potentially reduce the rate of antiviral resistance. Following screening, 137 articles were included in qualitative synthesis. Of the included studies, articles that examined the relationship between viral resistance to first-line treatments and potential second-line treatments in HSV were included. The Cochrane risk-of-bias tool for randomized trials was used to assess risk of bias. Due to the heterogeneity of study designs, a meta-analysis of the studies was not performed. The dates in which accepted studies were published spanned from 2015-2021. In terms of sample characteristics, the majority (72.26%) of studies used Vero cells. When looking at the viruses on which the interventions were tested, the majority (84.67%) used HSV-1, with (34.31%) of these studies reporting testing on resistant HSV strains. Regarding the effectiveness of the proposed interventions, 91.97% were effective as potential managements for resistant strains of HSV. Of the papers reviewed, nectin in 2.19% of the reviews had efficacy as a second-line treatments in HSV, amenamevir in 2.19%, methanol extract in 2.19%, monoclonal antibodies in 1.46%, arbidol in 1.46%, siRNA swarms in 1.46%, Cucumis melo sulfated pectin in 1.46%, and components from Olea europeae in 1.46%. In addition to this griffithsin in 1.46% was effective, Morus alba L. in 1.46%, using nucleosides in 1.46%, botryosphaeran in 1.46%, monoterpenes in 1.46%, almond skin extracts in 1.46%, bortezomib in 1.46%, flavonoid compounds in 1.46%, andessential oils were effective in 1.46%, but not effective in 0.73%. The available literature reviewed consistently supports the existence and potentiality of second-line treatments for HSV strains that are resistant to first-line treatments. Immunocompromised patients have been noted to be the population most often affected by drug-resistant variants of HSV. Subsequently, we found that HSV infections in this patient population are challenging to manage clinically effectively. The goal of this systematic review is to provide additional information to patients on the potentiality of second-line treatment in HSV strains resistant to first-line treatments, especially those who are immunocompromised. All patients,...

show abstract

“…Liu, Li, et al (2019) and Liu, Zhao, et al (2019) have designed the synthesis of a series of Janus‐type nucleosides 210a‐c by combining the natural genetic materials into a singular nucleoside structural unit (Scheme 35) and further evaluated their antiviral activity and investigated its SARs. Biological activity results revealed that compounds 210a and 210b exhibited excellent anti‐HSV activity with IC 50 values of 0.05 and 0.04 μg/ml, respectively.…”

Section: Influenza Virusesmentioning

confidence: 99%

“…Wang et al (2019) have synthesized a series of piperine alkaloid derivatives of the type 327a‐f and 330a‐f (Scheme 57), and their antiviral activities were investigated against TMV (Liu, Li, et al, 2019; Liu, Zhao, et al, 2019) for the first time. Most of the compounds exhibited higher antiviral activities than ribavirin but the compounds 327f , 329d , and 330d have shown same or higher antiviral activities than ningnanmycin.…”

Section: Plant Virusmentioning

confidence: 99%

Synthesis and antiviral activity of diverse heterocyclic scaffolds

Sharma

Utreja

2021

Chem Biol Drug Des

View full text Add to dashboard Cite

Heterocyclic moieties form a major part of organic chemistry as they are widely distributed in nature and have wide scale practical applications ranging from extensive clinical use to diverse fields such as medicine, agriculture, photochemistry, biocidal formulations, and polymer science. By virtue of their therapeutic properties, they could be employed in combating many infectious diseases. Among the common infectious diseases, viral infections are of great public health importance worldwide. Thus, there is an urgent need for the discovery and development of antiviral drugs and clinical methods to prevent various viral infections so as to increase the life expectancy. This review presents the comprehensive overview of the synthesis and antiviral activity of different heterocyclic compounds 2015 onwards, which aids in present knowledge and helps the researchers and other stakeholders to explore their field.

show abstract

Antiviral activities of Janus-type nucleosides and their related oxime-intermediates

Cited by 6 publications

References 41 publications

Unsubstituted Oximes as Potential Therapeutic Agents

Unsubstituted Oximes as Potential Therapeutic Agents

A Systematic Review of Second-Line Treatments in Antiviral Resistant Strains of HSV-1, HSV-2, and VZV

Synthesis and antiviral activity of diverse heterocyclic scaffolds

Contact Info

Product

Resources

About